Quarterly ResultAug 6, 2026, 08:09 AM
ALX Oncology Q2 Net Loss ($18.0M); Cash $153.4M; Clinical Progress
AI Summary
ALX Oncology Holdings Inc. reported its second quarter 2026 financial results, showing a reduced GAAP net loss of ($18.0) million, or ($0.13) per share, compared to ($25.9) million, or ($0.49) per share, in the prior year. The company maintained a strong financial position with $153.4 million in cash, cash equivalents, and investments, projected to fund operations through the first half of 2028. ALX Oncology also provided positive updates on its clinical programs, including the ASPEN-09-Breast Phase 2 trial and the ALX2004 Phase 1 trial, and announced leadership appointments and a debt refinancing that enhances financial flexibility.
Key Highlights
- Q2 2026 GAAP net loss was ($18.0) million, down from ($25.9) million in Q2 2025.
- Q2 2026 GAAP net loss per share was ($0.13), compared to ($0.49) in Q2 2025.
- Cash, cash equivalents, and investments totaled $153.4 million as of June 30, 2026.
- Cash runway is sufficient to fund operations through the first half of 2028.
- R&D expenses decreased to $13.1 million in Q2 2026 from $18.0 million in Q2 2025.
- ASPEN-09-Breast Phase 2 trial on track for mid-2027 topline data from 80 patients.
- ALX2004 Phase 1 trial expects initial safety data in the second half of 2026.
- Refinanced debt, securing up to $50 million facility and lowering cost of capital.
Price Impact
More from ALXO